The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae
Open Access
- 14 December 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 69 (7), 1101-1111
- https://doi.org/10.1093/cid/ciy1061
Abstract
Neisseria gonorrhoeae and Neisseria meningitidis are closely-related bacteria that cause a significant global burden of disease. Control of gonorrhoea is becoming increasingly difficult, due to widespread antibiotic resistance. While vaccines are routinely used for N. meningitidis, no vaccine is available for N. gonorrhoeae. Recently, the outer membrane vesicle (OMV) meningococcal B vaccine, MeNZB, was reported to be associated with reduced rates of gonorrhoea following a mass vaccination campaign in New Zealand. To probe the basis for this protection, we assessed the cross-reactivity to N. gonorrhoeae of serum raised to the meningococcal vaccine Bexsero, which contains the MeNZB OMV component plus 3 recombinant antigens (Neisseria adhesin A, factor H binding protein [fHbp]-GNA2091, and Neisserial heparin binding antigen [NHBA]-GNA1030). A bioinformatic analysis was performed to assess the similarity of MeNZB OMV and Bexsero antigens to gonococcal proteins. Rabbits were immunized with the OMV component or the 3 recombinant antigens of Bexsero, and Western blots and enzyme-linked immunosorbent assays were used to assess the generation of antibodies recognizing N. gonorrhoeae. Serum from humans immunized with Bexsero was investigated to assess the nature of the anti-gonococcal response. There is a high level of sequence identity between MeNZB OMV and Bexsero OMV antigens, and between the antigens and gonococcal proteins. NHBA is the only Bexsero recombinant antigen that is conserved and surfaced exposed in N. gonorrhoeae. Bexsero induces antibodies in humans that recognize gonococcal proteins. The anti-gonococcal antibodies induced by MeNZB-like OMV proteins could explain the previously-seen decrease in gonorrhoea following MeNZB vaccination. The high level of human anti-gonococcal NHBA antibodies generated by Bexsero vaccination may provide additional cross-protection against gonorrhoea.Keywords
Funding Information
- Australian National Health and Medical Research Council (1028326, 1099278)
This publication has 48 references indexed in Scilit:
- Immunization against a Saccharide Epitope Accelerates Clearance of Experimental Gonococcal InfectionPLoS Pathogens, 2013
- Distinct Binding and Immunogenic Properties of the Gonococcal Homologue of Meningococcal Factor H Binding ProteinPLoS Pathogens, 2013
- Conservation of Meningococcal Antigens in the Genus NeisseriamBio, 2013
- Effectiveness of a vaccination programme for an epidemic of meningococcal B in New ZealandVaccine, 2011
- BIGSdb: Scalable analysis of bacterial genome variation at the population levelBMC Bioinformatics, 2010
- Biological Functions and Biogenesis of Secreted Bacterial Outer Membrane VesiclesAnnual Review of Microbiology, 2010
- Vaccine-Induced Opsonophagocytic Immunity to Neisseria meningitidis Group BClinical and Vaccine Immunology, 2008
- Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle VaccinesClinical and Vaccine Immunology, 2007
- A universal vaccine for serogroup B meningococcusProceedings of the National Academy of Sciences of the United States of America, 2006
- The VR2 Epitope on the PorA P1.7-2,4 Protein Is the Major Target for the Immune Response Elicited by the Strain-Specific Group B Meningococcal Vaccine MeNZBClinical and Vaccine Immunology, 2006